Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NextCure, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
NXTC
Nasdaq
2830
www.nextcure.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NextCure, Inc.
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
- Jan 10th, 2025 1:05 pm
NextCure Announces Acceptance of IND Application for LNCB74
- Dec 10th, 2024 1:05 pm
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
- Nov 26th, 2024 12:00 pm
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
- Nov 19th, 2024 1:05 pm
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
- Nov 7th, 2024 9:05 pm
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
- Nov 5th, 2024 9:05 pm
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
- Oct 4th, 2024 1:05 pm
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
- Sep 16th, 2024 12:05 pm
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
- Sep 3rd, 2024 11:16 am
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
- Aug 1st, 2024 8:05 pm
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- Jun 20th, 2024 8:10 pm
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
- May 30th, 2024 8:05 pm
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
- May 2nd, 2024 8:05 pm
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
- Apr 24th, 2024 8:05 pm
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
- Apr 8th, 2024 11:00 am
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
- Apr 4th, 2024 11:05 am
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 11:00 am
Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
- Mar 27th, 2024 10:46 am
Wall Street’s Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
- Mar 23rd, 2024 10:00 am
NextCure to lay off 37% of staff, dial back research plans
- Mar 21st, 2024 3:22 pm
Scroll